Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

The founder said that 50% of enrolled patients in the Phase 3 bladder cancer study reached an evaluable efficacy endpoint, ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...

Explore new findings on bladder cancer and inflammation's role in immune suppression. Discover insights to improve treatment.

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a ...